Why Banking More Cells is Better

LifebankUSA is the only stem cell bank to have pioneered the advanced technology used to collect stem cells from placental blood. Banking placental stem cells in addition to cord blood increases the total number of stem cells collected.

  1. Transplanting more stem cells increases the likelihood of transplant success and survival.1,2,3 Compared to cord blood banking alone, placental and cord blood banking yields 60-70% more of a certain type of stem cell called a CD34+ stem cell.4 Studies show that transplanting more CD34+ stem cells can lead to a significant survival advantage in transplant patients.5
Study results depicting survival probability with stem cell treatment.

These findings are from a study of 102 patients at the University of Minnesota School of Medicine and Cancer Center.5

  1. Having more cells available offers the potential for multiple treatments for your child or a close family member (blood relative)—should they need it.
  2. Placental and cord blood, along with placental tissue, contain mesenchymal stem cells (MSCs) and mesenchymal-like stem cells, which have the remarkable ability to transform into many other types of cells and tissues. These types of stem cells have the potential to revolutionize regenerative medicine treatments in the near future.6,7,8 By banking placental stem cells, placental tissue, and cord blood, you ensure that you save more MSCs and mesenchymal-like stem cells so that your child and your family can benefit from future treatments as they become available.

Learn more about the power of the placenta, our services, and our unique approach by downloading our FREE LifebankUSA Quick Guide to stem cell banking.

It's a great time to be expecting.

Review our comprehensive cord blood, placental stem cells, and tissue banking options.

References
  1. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transpl. 2006; 38(2):83-93.
  2. Scaradavou A, on behalf of the National Cord Blood Program. Unrelated umbilical cord blood unit selection. Semin Hematol. 47; 13-21.
  3. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol. 2006; 18:565-570.
  4. Data on File, LifebankUSA. Median increase; 2016
  5. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NK, Davies SM. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002; 100(5):1611-1618.
  6. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal Stem Cells in Regenerative Medicine: Opportunities and Challenges for Articular Cartilage and Intervertebral Disc Tissue Engineering. J Cell Physiol. 2010; 222(1):23-32.
  7. Yen BL, Huang H-I, Chien C-C, Jui H-Y, Ko B-S, Yao M, Shun C-T, Yen M-L, Lee M-C, Chen Y-C. Isolation of multipotent cells from human term placenta. Stem Cells. 2005; 23(1):3-9.
  8. daSilva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008; 26(9):2287-2299.